{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:38:37Z","timestamp":1763707117476,"version":"3.45.0"},"reference-count":36,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T00:00:00Z","timestamp":1763683200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to evaluate the utilization of medical cannabis in a pediatric population and compare short-term persistence rates with those in adolescents and young adults.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>In this retrospective, nationwide cohort study supplemented by data from an open-label study of children with ASD, patient cases under 12\u00a0years of age who received medical cannabis treatment between 2018 and 2022 were analyzed. The primary outcome assessed was treatment persistence within the first 3\u00a0months. Secondary outcomes included changes in THC ratios, amounts dispensed, and reasons for treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The patient population consisted of 1,341 children using medical cannabis for ASD (751), epilepsy (330), Tourette syndrome (165), and pediatric cancer (95). Out of 3,007 consecutive medical cannabis sessions, the adjusted hazard ratio for discontinuation in the first 3\u00a0months was 0.83 (95% CI [0.71\u20130.96], p = 0.01) for young adults compared to children. Approximately 60%\u201370% of children discontinued therapy within the first 6\u00a0months. Significant alterations in THC ratios or dispensed amounts were observed in most sessions within the initial 6\u00a0months. In the open-label study dataset, most treatment discontinuations were primarily attributed to adverse effects and a perceived lack of therapeutic efficacy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our findings suggest that short-term persistence of medical cannabis therapy is lower in children compared to adolescents and young adults. Moreover, many pediatric patients required adjustments to their THC ratios and showed a high frequency of treatment discontinuation. These observations underscore the importance of targeted strategies to improve medical cannabis treatment effectiveness and adherence in the pediatric population. Although MC may offer therapeutic benefits for pediatric patients, our findings emphasize the importance of careful patient selection and close medical follow-up to optimize clinical outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fphar.2025.1646560","type":"journal-article","created":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:20Z","timestamp":1763706560000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Medical cannabis utilization in children \u2013 a study based on a nationwide cohort"],"prefix":"10.3389","volume":"16","author":[{"given":"Nir","family":"Treves","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noa","family":"Yakirevich-Amir","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karel","family":"Allegaert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John N.","family":"van den Anker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elkana","family":"Kohn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maya","family":"Berlin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ariela","family":"Hazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elyad","family":"Davidson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matitiahu","family":"Berkovitch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omer","family":"Bonne","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Orit E.","family":"Stolar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ilan","family":"Matok","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,11,21]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.3390\/jcm8111819","article-title":"Medical cannabis for older patients\u2014treatment protocol and initial results","volume":"8","author":"Abuhasira","year":"2019","journal-title":"J. Clin. Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"157","DOI":"10.3390\/CANCERS13010157","article-title":"The role of cannabinoids as anticancer agents in pediatric oncology","volume":"13","author":"Andradas","year":"2021","journal-title":"Cancers"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1007\/s10803-018-3808-2","article-title":"Brief report: Cannabidiol-rich cannabis in children with autism spectrum disorder and severe behavioral Problems-A retrospective feasibility study","volume":"49","author":"Aran","year":"2019","journal-title":"J. Autism Dev. Disord."},{"key":"B4","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1186\/s13229-021-00420-2","article-title":"Cannabinoid treatment for autism: a proof-of-concept randomized trial","volume":"12","author":"Aran","year":"2021","journal-title":"Mol. Autism"},{"key":"B5","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1089\/CAN.2022.0112","article-title":"Use of Medical Cannabis in Patients with Gilles de la Tourette\u2019s Syndrome in a Real-World Setting","volume":"9","author":"Barchel","year":"2024","journal-title":"Cannabis Cannabinoid Res."},{"key":"B6","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1097\/WCO.0000000000000660","article-title":"Cannabinoid therapy in epilepsy","volume":"32","author":"Billakota","year":"2019","journal-title":"Curr. Opin. Neurol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.3390\/HEALTHCARE10081553","article-title":"Cannabis use in autism: reasons for concern about risk for psychosis","volume":"10","author":"Bortoletto","year":"2022","journal-title":"Healthcare"},{"key":"B8","doi-asserted-by":"publisher","first-page":"6589","DOI":"10.1007\/S00520-021-06202-Z","article-title":"Medical cannabis in pediatric oncology: a survey of patients and caregivers","volume":"29","author":"Chapman","year":"2021","journal-title":"Support Care Cancer"},{"key":"B9","doi-asserted-by":"publisher","first-page":"3656","DOI":"10.1002\/CNCR.34920","article-title":"Cannabinoids for symptom management in children with cancer: a systematic review and meta-analysis","volume":"129","author":"Chhabra","year":"2023","journal-title":"Cancer"},{"key":"B10","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/S42238-022-00142-Z","article-title":"Medical cannabis regulation: an overview of models around the world with emphasis on the Brazilian scenario","volume":"4","author":"de Souza","year":"2022","journal-title":"J. Cannabis Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"2011","DOI":"10.1056\/NEJMOA1611618","article-title":"Trial of cannabidiol for drug-resistant seizures in the Dravet syndrome","volume":"376","author":"Devinsky","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"B12","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1111\/BCP.12753","article-title":"Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics","volume":"81","author":"Donovan","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"B13","unstructured":""},{"key":"B14","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3122\/JABFM.2012.01.110019","article-title":"An assessment of the hawthorne effect in practice-based research","volume":"25","author":"Fernald","year":"2012","journal-title":"J. Am. Board Fam. Med."},{"key":"B15","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1038\/S41398-022-02104-8","article-title":"Children and adolescents with ASD treated with CBD-rich cannabis exhibit significant improvements particularly in social symptoms: an open label study","volume":"12","author":"Hacohen","year":"2022","journal-title":"Transl. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"103526","DOI":"10.1016\/J.CITIES.2021.103526","article-title":"Urban diversity and epidemic resilience: the case of the COVID-19","volume":"122","author":"Hananel","year":"2022","journal-title":"Cities"},{"key":"B17","unstructured":""},{"key":"B18","article-title":"Licenses and prescriptions of cannabis products","year":"","journal-title":"Hebrew"},{"key":"B19","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/35081509","article-title":"Functional brain development in humans","volume":"2","author":"Johnson","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"88","DOI":"10.17226\/24625","article-title":"The health effects of cannabis and cannabinoids: the current state of evidence and recommendations for research","volume":"15","author":"Klimkiewicz","year":"2017","journal-title":"Psychiatria"},{"key":"B21","first-page":"87","article-title":"Jupyter notebooks \u2013 a publishing format for reproducible computational workflows","volume-title":"Positioning and power in academic publishing: players, agents and agendas - Proceedings of the 20th international conference on electronic publishing, ELPUB 2016","author":"Kluyver","year":"2016"},{"key":"B22","doi-asserted-by":"publisher","first-page":"633168","DOI":"10.3389\/fphar.2021.633168","article-title":"Practical strategies using medical cannabis to reduce harms associated with long term opioid use in chronic pain","volume":"12","author":"MacCallum","year":"2021","journal-title":"Front. Pharmacol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"359","DOI":"10.3390\/PH15030359","article-title":"Medical cannabis in pediatric oncology: friend or foe?","volume":"15","author":"Malach","year":"2022","journal-title":"Pharmaceuticals"},{"key":"B24","doi-asserted-by":"publisher","first-page":"56","DOI":"10.25080\/MAJORA-92BF1922-00A","article-title":"Data structures for statistical computing in python","author":"McKinney","year":"2010","journal-title":"scipy"},{"key":"B25","year":""},{"key":"B26","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1080\/08880018.2019.1630537","article-title":"Medical marijuana use for pediatric oncology patients: single institution experience","volume":"36","author":"Ofir","year":"2019","journal-title":"Pediatr. Hematol. Oncol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1016\/j.yebeh.2018.01.026","article-title":"Efficacy of artisanal preparations of cannabidiol for the treatment of epilepsy: practical experiences in a tertiary medical center","volume":"80","author":"Porcari","year":"2018","journal-title":"Epilepsy Behav."},{"key":"B28","doi-asserted-by":"publisher","first-page":"505","DOI":"10.1007\/s00787-023-02169-w","article-title":"Efficacy of cannabinoids in neurodevelopmental and neuropsychiatric disorders among children and adolescents: a systematic review","volume":"33","author":"Rice","year":"2024","journal-title":"Eur. Child. Adolesc. Psychiatry"},{"key":"B29","doi-asserted-by":"publisher","first-page":"12","DOI":"10.21037\/pm-20-70","article-title":"A critical narrative review of medical cannabis in pediatrics beyond epilepsy, part III: chemotherapy-induced nausea and vomiting and inflammatory bowel disease","volume":"3","author":"Simonian","year":"2020","journal-title":"Pediatr. Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"977484","DOI":"10.3389\/FPHAR.2022.977484","article-title":"Medical cannabis for the treatment of comorbid symptoms in children with autism spectrum disorder: an interim analysis of biochemical safety","volume":"13","author":"Stolar","year":"2022","journal-title":"Front. Pharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1455","DOI":"10.1111\/BPH.14440","article-title":"Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors","volume":"176","author":"Tham","year":"2019","journal-title":"Br. J. Pharmacol."},{"key":"B32","unstructured":"Survival analysis\n          \n          \n            \n              Therneau\n              T. M.\n            \n          \n          \n          2024"},{"key":"B33","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1111\/epi.14670","article-title":"Cannabidiol in patients with Lennox-Gastaut syndrome: interim analysis of an open-label extension study","volume":"60","author":"Thiele","year":"2019","journal-title":"Epilepsia"},{"key":"B34","doi-asserted-by":"publisher","first-page":"23462","DOI":"10.1038\/S41598-021-02770-6","article-title":"Efficacy and safety of medical cannabinoids in children: a systematic review and meta-analysis","volume":"11","author":"Treves","year":"2021","journal-title":"Sci. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"416167","DOI":"10.3389\/FPHAR.2018.01259\/FULL","article-title":"Cannabinoids and pain: new insights from old molecules","volume":"9","author":"Vu\u010dkovic","year":"2018","journal-title":"Front. Pharmacol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"3503","DOI":"10.1007\/s00520-020-05306-2","article-title":"Cannabis use in pediatric cancer patients: what are they reading? A review of the online literature","volume":"28","author":"Yeung","year":"2020","journal-title":"Support. Care Cancer"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646560\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,21]],"date-time":"2025-11-21T06:29:22Z","timestamp":1763706562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1646560\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,21]]},"references-count":36,"alternative-id":["10.3389\/fphar.2025.1646560"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1646560","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,21]]},"article-number":"1646560"}}